As expected, statistically significant differences were found between patients with RA-ILD- and RA-ILD+ regarding the following clinical features: RF and ACPA status, CRP levels, forced expiratory volume in one second /forced vital capacity (FEV1/FVC) (% predicted), diffusing capacity of the lung for carbon monoxide (DLCO) (% predicted), and therapies received (Table 1). Here, PRTN3 is linked to interstitial lung disease.